The efficacy of therapeutics in human healthcare has improved dramatically over the last 25 years thanks mainly to the introduction of innovative biological drugs.
Biological drugs will equally benefit animal health provided that cost-effective manufacturing solutions become available.
With the combined effects of the increasing worldwide demand for safe and healthy food, the pressure to drastically reduce the use of antibiotics and the growing concern around zoonotic disease prevention, efficient treatments and prevention modalities for livestock animals have become a key factor for food supply and environmental sustainability.
Drugs produced in the milk of animals were approved as human therapeutics by the FDA in 2006 and by the EMA in 2009 (Atryn® originally developed at the time by GTC Biotherapeutics, now LFB USA (LFB Group) and its proprietary rPRO technology™). By adapting this rPRO® technology for veterinary use, Bio-Sourcing will create an innovative and safe route for a number of applications. Bio-Sourcing’s makes it possible for Animal Health companies to exploit its technology license from LFB to produce better and more affordable drugs.